Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -73.19% is 28% below its 5-year average of -56.96%, around the middle of its 5-year range (-108.53%–-23.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.85% below its 12-month average of -68.50%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-06-30): -73.19%.
RETURN ON EQUITY (ROE)
-73.19%
RETURN ON EQUITY (ROE) AVG TTM
-68.50%
RETURN ON EQUITY (ROE) AVG 3Y
-68.63%
RETURN ON EQUITY (ROE) AVG 5Y
-56.96%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.85%
CURRENT VS 3Y AVG
-6.64%
CURRENT VS 5Y AVG
-28.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.95%
median of 556 covered companies
CURRENT VS SECTOR MEDIAN
-87.90%
vs the sector median at left
Immunovant, Inc.
Market Cap
$6.72B
Return on Equity (ROE)
-73.19%
TTM Avg
-68.50%
3Y Avg
-68.63%
5Y Avg
-56.96%
Market Cap
$6.67B
Return on Equity (ROE)
33.11%
TTM Avg
27.03%
3Y Avg
27.48%
5Y Avg
31.41%
Market Cap
$6.61B
Return on Equity (ROE)
-43.83%
TTM Avg
25.09%
3Y Avg
5.57%
5Y Avg
0.40%
Market Cap
$6.52B
Return on Equity (ROE)
20.99%
TTM Avg
25.07%
3Y Avg
24.12%
5Y Avg
13.08%
Market Cap
$6.50B
Return on Equity (ROE)
476.51%
TTM Avg
2.59%
3Y Avg
-115.75%
5Y Avg
-71.67%
Market Cap
$7.03B
Return on Equity (ROE)
3.66%
TTM Avg
19.17%
3Y Avg
13.19%
5Y Avg
6.34%
Market Cap
$6.01B
Return on Equity (ROE)
-15.40%
TTM Avg
-48.41%
3Y Avg
-63.30%
5Y Avg
-53.67%
Market Cap
$7.38B
Return on Equity (ROE)
-128.44%
TTM Avg
-77.53%
3Y Avg
-74.21%
5Y Avg
-60.06%
Market Cap
$5.96B
Return on Equity (ROE)
20.38%
TTM Avg
5.87%
3Y Avg
3.40%
5Y Avg
3.36%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.72B | -73.19% | -68.50% | -68.63% | -56.96% |
| Chemed Corporation (CHE)vs › | $6.67B | 33.11% | 27.03% | 27.48% | 31.41% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.61B | -43.83% | 25.09% | 5.57% | 0.40% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.52B | 20.99% | 25.07% | 24.12% | 13.08% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.50B | 476.51% | 2.59% | -115.75% | -71.67% |
| Alkermes plc (ALKS)vs › | $7.03B | 3.66% | 19.17% | 13.19% | 6.34% |
| GRAIL Inc. (GRAL)vs › | $6.01B | -15.40% | -48.41% | -63.30% | -53.67% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.38B | -128.44% | -77.53% | -74.21% | -60.06% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.96B | 20.38% | 5.87% | 3.40% | 3.36% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.88B | -39.33% | -54.18% | -65.89% | -59.69% |
ROE
-73.2%
ROA
-63.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -73.19% |
| 2026-03-31 | -59.30% |
| 2025-12-31 | -47.07% |
| 2025-09-30 | -89.41% |
| 2025-06-30 | -73.50% |
| 2025-03-31 | -58.50% |
| 2024-12-31 | -108.53% |
| 2024-09-30 | -71.93% |
| 2024-06-30 | -50.04% |
| 2024-03-31 | -41.98% |
| 2023-12-31 | -35.84% |
| 2023-09-30 | -101.37% |
| 2023-06-30 | -81.54% |
| 2023-03-31 | -58.20% |
| 2022-12-31 | -47.92% |
| 2022-09-30 | -44.69% |
| 2022-06-30 | -38.18% |
| 2022-03-31 | -33.36% |
| 2021-12-31 | -27.26% |
| 2021-09-30 | -23.88% |
| 2021-06-30 | -30.42% |
| 2021-03-31 | -27.44% |
| 2020-12-31 | -24.10% |
| 2020-09-30 | -18.10% |
| 2020-06-30 | -21.82% |
| 2020-03-31 | -33.53% |
| 2019-12-31 | -9.82% |
| 2019-09-30 | -7.53% |
| 2019-06-30 | -13.25% |
